Professional
Added to YB: 2025-07-15
Pitch date: 2025-07-10
TECH [neutral]
Bio-Techne Corporation
+8.94%
current return
Author Info
No bio for this author
Company Info
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
Market Cap
$9.4B
Pitch Price
$53.46
Price Target
78.00 (+34%)
Dividend
0.53%
EV/EBITDA
26.95
P/E
115.41
EV/Sales
7.85
Sector
Life Sciences Tools and Services
Category
growth
Headwaters Capital Management Portfolio Holding: Bio-Techne Corporation
TECH (holding update): Market leader in life sciences reagents with 80% recurring revenue. Stock pressured by NIH cuts impacting 12% of rev from US academia. Likely flat FY'26 before growth resumes in FY'27 as C> biz (+20% growth) propels recovery. PT $78 (57% upside). M&A comparable at 30x EBITDA = $82 (64% upside).
Read full article (5 min)